A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

Trial Profile

A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
  • Acronyms PASCAL
  • Sponsors UCB
  • Most Recent Events

    • 05 Feb 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.
    • 05 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Feb 2019.
    • 11 Nov 2016 Results will be presented at the 2016 American College of Rheumatology/Association for Rheumatology Health Professionals (ACR/ARHP) Annual Meeting, as per a UCB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top